Life cycle heterogeneity in animal models of human papillomavirus-associated disease by Peh, W.L. et al.
JOURNAL OF VIROLOGY, Oct. 2002, p. 10401–10416 Vol. 76, No. 20
0022-538X/02/$04.000 DOI: 10.1128/JVI.76.20.10401–10416.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Life Cycle Heterogeneity in Animal Models of Human
Papillomavirus-Associated Disease
Woei Ling Peh,
1 Kate Middleton,
1 Neil Christensen,
2 Philip Nicholls,
3 Kiyofumi Egawa,
4 Karl Sotlar,
5
Janet Brandsma,
6 Alan Percival,
7 Jon Lewis,
8 Wen Jun Liu,
9 and John Doorbar
1*
National Institute for Medical Research, The Ridgeway, Mill Hill, London,
1 Department of Podiatry, Nene College, Northampton,
7
and Roche Discovery, Welwyn Garden City, Welwyn,
8 United Kingdom; The Jake Gittlen Cancer Research Institute, The Milton
S. Hershey Medical Center, Hershey, Pennsylvania
2; Division of Veterinary and Biomedical Sciences, Murdoch University,
Murdoch, Western Australia,
3 and Centre for Immunology and Cancer Research, University of Queensland, Princess
Alexandra Hospital, Woolloongabba,
9 Australia; Department of Dermatology, Kumamoto University School of
Medicine, Kumamoto, Japan
4; Institute for Pathology, Tubingen, Germany
5; and Yale University School
of Medicine, New Haven, Connecticut
6
Received 25 March 2002/Accepted 3 July 2002
Animal papillomaviruses are widely used as models to study papillomavirus infection in humans despite differ-
ences in genome organization and tissue tropism. Here, we have investigated the extent to which animal models of
papillomavirus infection resemble human disease by comparing the life cycles of 10 different papillomavirus types.
Three phases in the life cycles of all viruses were apparent using antibodies that distinguish between early events,
the onset of viral genome ampliﬁcation, and the expression of capsid proteins. The initiation of these phases follows
a highly ordered pattern that appears important for the production of virus particles. The viruses examined
included canine oral papillomavirus, rabbit oral papillomavirus (ROPV), cottontail rabbit papillomavirus (CRPV),
bovine papillomavirus type 1, and human papillomavirus types 1, 2, 11, and 16. Each papillomavirus type showed
a distinctive gene expression pattern that could be explained in part by differences in tissue tropism, transmission
route, and persistence. As the timing of life cycle events affects the accessibility of viral antigens to the immune
system, the ideal model system should resemble human mucosal infection if vaccine design is to be effective. Of the
model systems examined here, only ROPV had a tissue tropism and a life cycle organization that resembled those
of the human mucosal types. ROPV appears most appropriate for studies of the life cycles of mucosal papilloma-
virus types and for the development of prophylactic vaccines. The persistence of abortive infections caused by CRPV
offers advantages for the development of therapeutic vaccines.
Human papillomaviruses (HPVs) are associated with epithe-
lial lesions that can progress to high-grade neoplasia and can-
cer (22, 103). Cancer of the cervix is caused by high-risk pap-
illomavirus types, such as HPV type 16 (HPV16), and is the
second-most-common female cancer worldwide. Low-risk hu-
man papillomavirus types, such as HPV11, cause genital warts
(88). Genital warts afﬂict 1 in 200 young adults and in many
countries are the most common sexually transmitted disease
(51). They are difﬁcult to treat and often recur.
The prevalence of HPV infections, and the severity to which
some lesions can progress, has led to the development of
model systems in which to study virus infection. Papillomavi-
ruses infect epithelial tissue, and their life cycle is regulated as
the infected epithelial cell differentiates. This leads to vegeta-
tive viral genome ampliﬁcation in the intermediate epithelial
layers and the assembly of infectious virions closer to the
epithelial surface. Model systems enable the roles of viral pro-
teins to be examined during productive infection and allow the
development of strategies for the prevention and treatment of
HPV-associated disease.
Two types of model system are currently in use. The ﬁrst
uses organotypic raft culture or xenotransplantation to support
the growth of differentiating human keratinocytes and produc-
tive infection (50, 77). Such approaches approximate in vivo
infection but are technically demanding and depend on the
availability of human tissue. The second type of model makes
use of animal papillomaviruses that cause lesions similar to
those found in humans (11, 90). This approach is suited to both
therapeutic- and prophylactic-vaccine development, as the
course of infection can be monitored in an immunocompetent
host. Cottontail rabbit papillomavirus (CRPV) has been used
extensively for this purpose and has also provided insights into
the roles of viral gene products during productive and latent
infection and during the progression to cancer (12–14, 33, 69,
104, 107). More recently, canine oral papillomavirus (COPV)
has been used for prophylactic-vaccination studies despite the
cost of housing large animals and the inability of COPV to
infect genital tissue (91, 105).
Although animal models have been used to study infection
in humans, there has been no molecular assessment of the
extent to which these model systems resemble the HPV infec-
tions they are supposed to mimic. This is particularly relevant,
as recent work has suggested that rabbit oral papillomavirus
(ROPV) may be a more appropriate model of productive hu-
man genital infections than COPV or CRPV (28, 29). ROPV
infects oral and genital mucosa and does not contain the 1.5-kb
noncoding region 2 that is unique to COPV (29, 34). COPV
and CRPV do not cause lesions at genital sites (34, 97).
In this study, we have used three markers of the virus life
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maviruses used to study infection in humans. In the lower
layers of infected tissue, expression of E6 and E7 (and maybe
also E5) leads to the up-regulation of E2F-activated genes,
such as those for PCNA and cyclin A. Such proteins are sur-
rogate markers of viral gene expression, and their presence
identiﬁes cells supporting early events during the virus life
cycle (60). E4 expression follows activation of the differentia-
tion-dependent promoter (26, 71). Its appearance has been
reported to coincide with the onset of vegetative viral genome
ampliﬁcation and marks the initiation of late events (42). Only
upon further differentiation is the major capsid protein ex-
pressed, allowing the assembly of infectious virions and their
release from the epithelial surface. By mapping life cycle
events in lesions caused by animal and human papillomavi-
ruses, we have revealed an unexpected degree of heterogeneity
among the viruses. Late events begin in the basal layer in
lesions caused by COPV but can be retarded until the super-
ﬁcial layers in lesions caused by HPV16. Of the animal models
examined, the productive life cycle of ROPV appears to re-
semble those of HPV16 and HPV11 most closely.
MATERIALS AND METHODS
Production of expression constructs. E1∧E4 sequences were predicted from
alignment data (ROPV, COPV, HPV63, and HPV65) (44, 108) or from the
results of RNA-mapping experiments (HPV11, CRPV, and bovine papillomavi-
rus type 1 [BPV1]) (3, 26, 45, 102). DNA comprising the full-length spliced
E1∧E4 gene was cloned between the SalI and EcoRI sites of pGex4T-1 (Amer-
sham, Little Chalfont, United Kingdom) or pMalc (New England Biolabs) using
standard methods. The primers used to prepare the E1∧E4 genes of each virus
type are listed below. For BPV1 E1∧E4, the forward primer was BPVE14P1
(AGG ATC CGA ATT CGC AAA CGA TAA AGA GAT CGC CCA GAC
GGA) and the reverse primer was BPVE14P2 (GCA ACC CGG GTC GAC
CTA TCA CTG GTT CTT CCT CTG TG). For CRPV, the forward primer was
CRE4P1 (AGG ATC CGA ATT CGC TGA AGC TCC CCC CAG CCG CTG
GTC A) and the reverse primer was CRE4P2 (ACC CGG GTC GAC CTA TTA
TAA GCT CGC GAA GCC GTC TAT). For COPV, the forward primer was
COE14P1 (AGG ATC CGA ATT CGC GGC TAG AAA AGT GCC GCC
GGA ACC TCC G) and the reverse primer was COE14P2 (GCA ACC CGG
GTC GAC CTA CTA AAA CAA CAA CTG GGG GAT CGT). For HPV11,
the forward primer was H11E14P1 (AGG ATC CGA ATT CGC GGA CGA
TTC AGC ACT GTA CGA GAA GTA TCC) and the reverse primer was
H11E14P2 (GCA ACC CGG GTC GAC CTA CTA TAG GCG TAG CTG
CAC TGT GAC). For HPV63, the forward primer was H63E14P1 (AGG ATC
CGA ATT CAC CGA CAG AGCT CCC CAC TAC GGA CTT CTG GG) and
the reverse primer was H63E14P2 (GCA ACC CGG GTC GAC CTA TTA
TGG GTG GAT CCC GAG CCT). For HPV65, the forward primer was
H65E14P1 (AGG ATC CGA ATT CGC AGA TAA AGC TCA ACA AAC
ACC CCC TCC TTC) and the reverse primer was H65E14P2 (GCA ACC CGG
GTC GAC CTA TCA TGG GTG GAT CCC TAG CTT). For ROPV, the
forward primer was ROE14P1 (AGG ATC CGA ATT CGC TGA AGC TCA
ACC CCC CTA CGG C) and the reverse primer was ROE14P2 (GCA ACC
CGG GTC GAC CTA TCA CTG GCG GAT CCC GAG). The integrity of the
clones was established by automatic DNA sequencing using an ABI machine.
Generation of E4-speciﬁc antibodies. Glutathione S-transferase (GST)–
E1∧E4 fusion proteins were used as antigens to generate speciﬁcE 1 ∧E4 anti-
bodies in rabbits (BPV-1, COPV, HPV-11, HPV63, and HPV65) or rats (CRPV
and ROPV). Rabbits were immunized at multiple subcutaneous sites with 250 g
of protein in Freund’s complete adjuvant, followed by booster immunizations at
14-day intervals with the 250-g antigen in Freund’s incomplete adjuvant. An-
tibody titers were evaluated by ELISA 14 days after the third injection, and
immunization was continued if low antibody titers were found. Rat immunization
was carried out in the same way except that 50 g of protein was used per
immunization. Preimmune serum was collected before the immunization proto-
col was started and was used as a control in the immunostaining experiments.
Antibodies were also generated against keyhole limpet hemocyanin-conjugated
peptides in rabbits and rats using the immunization protocol described above.
Peptide conjugation was carried out using m-maleimidobenzoyl-N-hydroxysuc-
cinimide ester (Sulfo-MBS; Perbio) using an established protocol (55). Antibod-
ies were made against the ﬁrst 12 N-terminal amino acids of the CRPV (ac-A
EAPPSRWSVPLCamide) and BPV-1 E1E ˆ4 (ac-ANDKEIAQTESGCamide)
proteins and the last 12 C-terminal amino acids of BPV-1 E4 (RSSRPT
PQRKNQCamide). The methionine residue encoded by the initiation codon
was omitted from the N-terminal peptides and replaced by an acetyl group (ac)
in order to mimic the predicted in vivo modiﬁcation of the protein.
The speciﬁcities of antibodies were established by ELISA and Western blot-
ting using maltose binding protein-E1E ˆ4 fusion proteins or bovine serum albu-
min-conjugated peptides (conjugation was carried out using m-maleimidoben-
zoyl-N-hydroxysuccinimide ester (Sulfo-MBS; Perbio) as outlined above [55]).
For Western blots, 0.5 g of puriﬁed fusion protein (per well) was run on a
sodium dodecyl sulfate–10% polyacrylamide gel prior to being transferred to a
nitrocellulose membrane by semidry blotting (Bio-Rad). Test antisera were di-
luted 1:250 in phosphate-buffered saline (PBS) containing 2% nonfat dry milk
powder (Marvel), and blotting was carried out as described previously (55).
ELISAs were carried out using 0.5 g of protein (Falcon) per well essentially as
described by Harlow and Lane (55). Species-speciﬁc (anti-rabbit or anti-rat)
horseradish peroxidase-conjugated secondary antibodies (Amersham) were used
for detection, and horseradish peroxidase activity was visualized using FAST
DAB tablets (Sigma, St. Louis, Mo.). Maltose binding protein or bovine serum
albumin was used as a negative control to establish that the reactivity was speciﬁc
for E4.
Lesions caused by human and animal papillomaviruses. Tissue biopsy spec-
imens ﬁxed in 10% neutral buffered formalin and embedded in parafﬁn wax were
cut into 5-m-thick sections and mounted on electrostatically charged slides
(BDH). Experimental lesions induced in cottontail rabbits (ﬁve were examined)
and in New Zealand White rabbits (nine were examined) were provided by two
of the authors (Neil Christensen and Janet Brandsma, respectively). Experimen-
tal lesions were induced at the cutaneous epithelium on the rabbits’ backs using
established procedures (12, 13). Naturally occurring COPV-induced oral papil-
FIG. 1. Heterogeneity in the timing of events during the life cycles of human and animal papillomaviruses. (A) Tissue sections from a mucosal
lesion caused by COPV (top row) and a cutaneous lesion caused by HPV2 (middle row) were double stained using antibodies to E4 (green) and
PCNA (red) before being counterstained with DAPI (blue) to visualize cell nuclei. Surrogate markers of E7 expression (PCNA) were conﬁned to
sporadic cells in the lowest parabasal layers. E4 (green) was ﬁrst detected in these cells as they migrated through the lower layers of the epithelium.
E4 was expressed in the basal layer in lesions caused by COPV and in a few cells above the basal layer in lesions caused by HPV2. Surrogate
markers of E7 were lost soon after the appearance of E4. The merged images (m) are shown at the left. A section through a cutaneous lesion
caused by CRPV is shown in the bottom row after immunostaining to detect PCNA (red) and in situ hybridization to detect viral genome
ampliﬁcation (blue). The nuclei were counterstained using Sytox green. Surrogate markers of E7 expression (PCNA) did not persist to the
epithelial surface and were lost soon after the onset of viral genome ampliﬁcation (blue). Genome ampliﬁcation began in the mid-spinous layers
in lesions caused by CRPV. The broken lines indicate the positions of the basal layers. The images were taken using a 10 (COPV and HPV2)
or 20 (COPV/m inset) objective. (B) Tissue sections from mucosal lesions caused by ROPV (top row), HPV11 (middle row), and HPV16 (bottom
row) were double stained with antibodies to E4 (green) and PCNA (red) before being counterstained with DAPI (blue) to visualize cell nuclei.
The merged images are shown at the left. In such lesions, surrogate markers of E7 expression (PCNA; red) usually persisted into the upper
epithelial layers but were lost following the expression of E4. E4 was rarely detected in the lower epithelial layers in lesions caused by HPV11 and
-16. Cells expressing both E4 and PCNA are indicated by arrows in the HPV11 and HPV16 images. The broken lines indicate the positions of the
basal layers. The images were taken using a 20 objective.
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to Philip Nicholls. Naturally occurring BPV-induced ﬁbropapillomas from cuta-
neous sites on the head and neck (four total) were provided by Wen Jun Liu.
Human verrucas caused by HPV1 (22 were examined for E1∧E4 expression),
HPV63 (3 were examined), and HPV65 (6 were examined) were provided by
Kiyofumi Egawa or were obtained from previously described sources (38, 42, 43).
Cutaneous warts caused by HPV2 (25 were examined for E1∧E4 expression)
were also obtained from these sources (38, 42, 43) or were provided by Alan
Percival. Low-grade squamous intraepithelial lesions (LSIL) caused by HPV16
(seven were examined) and HPV11 (ﬁve were examined) were provided by Karl
Sotlar or were obtained from previously described sources. Foreskin tissue in-
fected with HPV11 virions and propagated as skin grafts on SCID mice (seven
were examined) or under the kidney capsule of nude mice (six were examined)
was provided by John Lewis. Experimental COPV-induced lesions (8 oral lesions
were examined) and ROPV-induced lesions (22 oral and 2 penile lesions were
examined) were produced in dogs (beagles) or rabbits by tissue scariﬁcation and
inoculation of virions (29, 75). The propagation of HPV11 (six lesions were
examined), ROPV (two lesions were examined), and CRPV (two lesions were
examined) in infected tissue implanted under the kidney capsule of nude mice
was carried out according to established protocols (9, 28).
Use of polyclonal and monoclonal antibodies. Parafﬁn-embedded sections
were dewaxed in xylene (one time for 10 min followed by one time for 5 min) and
rehydrated by passage through graded alcohols (twice for 3 min each time in
100% ethanol and then for 2 min each in 90, 80, 50, and 30% ethanol) before
being placed in PBS (twice for 5 min each time). For the detection of E1E ˆ4i n
lesions caused by BPV, CRPV, ROPV, HPV11, HPV16, HPV63, and HPV65,
formalin-ﬁxed tissue sections were either microwaved three times for 5 min each
time (at 650 W) in citrate buffer (pH 6.0 for all E4 detection except CRPV, which
was carried out at pH 8.0) or heated in a domestic pressure cooker in the same
buffer for 3 to 6 min. The citrate buffer was prepared by adding 9 ml of 0.1 M
citric acid and 45 ml of 0.1 M sodium citrate to 500 ml of water. The sections
were subsequently blocked for1ha troom temperature using 10% fetal bovine
serum or 10% goat serum in PBS before being incubated with the monoclonal or
polyclonal antibodies. Epitope exposure was not necessary in order to visualize
E1E ˆ4 in lesions caused by COPV, HPV1, and HPV2. Polyclonal antibodies to
the E4 protein of BPV were used at dilutions of 1:100 to 1:150 (anti-GST-
E1∧E4) or 1:200 to 1:400 (anti-peptide), while those to the E4 protein of COPV
were used at a dilution of 1:600. Polyclonal antibodies to the E4 proteins of
CRPV and HPV11 were used at 1:100 dilution (anti-peptide and anti-GST-
E1E ˆ4), while those to the E4 protein of ROPV were used at a dilution of 1:400
(anti-GST-E1∧E4). Preimmune serum was used as a control.
Double staining was carried out following the incubation of tissue sections with
two different antibodies. In lesions caused by BPV, COPV, and HPV-11, E4 was
detected using E4-speciﬁc rabbit polyclonal serum and L1 was detected using the
mouse monoclonal antibody CAMVIR-1 (1:100 dilution; Pharmingen). Rabbit
polyclonal antibodies raised against BPV particles (1:100 dilution; DAKO) were
used to detect L1 in lesions caused by ROPV, while the L1 protein of CRPV was
detected using NZ264 serum (1:100 dilution; kindly provided by Francoise Bre-
itburd, Institut Pasteur, Paris, France). PCNA was detected using the mouse
monoclonal antibody PC10 (Neomarkers). Antibodies to cyclin A and MCM7
were obtained from commercial sources (Novocastra and Neomarkers). Incuba-
tion with primary antibodies was carried out for1ha troom temperature or
overnight at 4°C before the sections were washed (three times for 5 min each
time) in PBS containing 0.05% Tween 20.
Immunodetection of antibodies. Primary antibodies were detected using spe-
cies-speciﬁc secondary antibodies (1:50 dilution) conjugated to ﬂuorescein or
Texas red (Amersham), except where signal ampliﬁcation was necessary using
streptavidin ABC-alkaline phosphatase or horse radish peroxidase (DAKO). In
such instances, the section was incubated for1hi nt h epresence of a biotinylated
species-speciﬁc secondary antibody before being washed (three times for 5 min
each time) in Tris-buffered saline containing 0.05% Tween 20. A biotin-strepta-
vidin-alkaline phosphatase or horseradish peroxidase complex (DAKO) was then
added along with the nucleic acid stain Sytox green (125 nM in PBS) or DAPI
(4,6-diamidino-2-phenylindole; 500 nM) (Molecular Probes). The section was
then incubated for 30 min at room temperature before being washed (three times
for 5 min each time) in Tris-buffered saline containing 0.05% Tween 20 and
developed using Fast Red TR–Naphthol AS-MX (Sigma) or tyramide substrate
(NEN Life Science Products) both prepared according to the manufacturer’s
instructions. The colorimetric reaction was stopped when development was com-
plete by washing the section for 5 min in PBS.
DNA labeling and in situ hybridization. DNA probes for in situ hybridization
were labeled with either biotin (BioProbe Random Primed DNA Labeling system;
Enzo) or digoxigenin (DIG DNA Labeling and Detection kit; Roche Molecular
Biochemicals) according to the manufacturer’s instructions. Full-length linearized
papillomavirus DNA was used as a template for random primer labeling. In situ
hybridization reactions were performed on parafﬁn-embedded formalin-ﬁxed tissue
sections after dewaxing and rehydration (as described above). The sections were
then digested for 15 min at 37°C using proteinase K (50 g/ml) before being washed
in PBS (twice for 2 min each time) and air dried at room temperature. The labeled
DNA probes were diluted 1:25 in hybridization buffer (50% deionized formamide,
1 Denhardt’s, 5% dextran sulfate, 200 g of salmon sperm DNA/ml, 4 SSC [1
SSC is 0.15 M NaCl plus 0.015 M sodium citrate]) before being added to the sections.
The sections were then covered with glass coverslips, and sealed with cow gum (Cow
Prooﬁngs Ltd.), and heated at 93°C for 5 min. The slides were immediately
quenched in ice for 5 min and were then incubated overnight at 37°C in a humid
chamber. After removal of the cow gum, the coverslips were shaken off in 0.5 SSC
and the slides were washed in stringent wash buffers (50% formamide, 2 SSC,
0.05% Tween 20 [twice for 5 min each time] and 2SSC [twice for 5 min each time])
at 42°C. DIG-labeled DNA was detected using a Tyramide Signal Ampliﬁcation-
Direct system (BlueFISH or RedFISH) (NEN Life Science Products) according to
the manufacturer’s instructions. Endogenous peroxidase activity was removed by
incubation in 3% hydrogen peroxide at room temperature for 10 min. Detection of
the DIG-conjugated probe was carried out using a horseradish peroxidase-conju-
gated antibody to DIG followed by development (8 min) in the presence of tyramide
substrate and propidium iodide. Biotin-labeled DNA was visualized using strepta-
vidin ABC-alkaline phosphatase and Fast Red substrate deposition as described
above.
RESULTS
Variation in the extent of early gene activity during the life
cycles of human and animal papillomaviruses. Following the
infection of basal keratinocytes, the viral early genes (E6, E7,
and maybe E5) are expressed from a promoter in the upstream
regulatory region (reviewed in references 58 and 65a). Al-
though these viral proteins are difﬁcult to detect because of
their low levels of expression, the cellular gene products they
induce can be readily identiﬁed (60). Such proteins are nor-
mally absent from differentiating epithelium, and their pres-
ence in warts is an indication of early viral gene activity. Three
E2F-activated gene products (cyclin A, MCM7, and PCNA)
were examined for their usefulness as markers of cells express-
FIG. 2. The onset of vegetative viral genome ampliﬁcation coincides closely with the expression of E4 in all papillomavirus infections.
(A) Tissue sections from a mucosal lesion caused by COPV and cutaneous lesions caused by HPV2, HPV65, and HPV63 were probed to detect
the presence of ampliﬁed viral DNA (red) and E4 (green). The nuclei were counterstained using DAPI (blue). Genome ampliﬁcation was generally
conﬁned to cells expressing E4 (green). In warts caused by COPV, HPV2, and HPV65, such cells were distributed sporadically throughout the
lesion. The broken lines indicate the positions of the basal layers. The images were taken using a 10 objective. The inset shows COPV E4 and
viral genome ampliﬁcation in the basal layer (green, E4; red, ampliﬁed viral DNA; blue, DAPI counterstain). The images were taken using a 40
objective. (B) Tissue section from a cutaneous lesion caused by CRPV and from mucosal lesions caused by ROPV, HPV11, and HPV16 were
probed by in situ hybridization to detect cells that had ampliﬁed viral DNA (red). E4 was detected by using speciﬁc antibodies to the E4 proteins
of each virus type (green), and the nuclei were counterstained using DAPI (blue). E4 expression and viral genome ampliﬁcation were restricted
to a band of cells in the middle and upper epithelial layers. The broken lines indicate the positions of the basal layers. The images were taken using
a1 0  objective.
VOL. 76, 2002 PAPILLOMAVIRUS MODEL SYSTEMS 10405ing E6, E7, and E5 in human and animal tissues. Antibodies to
all three proteins gave similar patterns of staining, but that to
PCNA (PC10; Neomarkers) showed good cross-reactivity be-
tween species and could detect the protein in bovine, canine,
and rabbit tissue. PCNA was present in the basal layers of
infected and uninfected epithelium but extended into the up-
per epithelial layers in papilloma tissue (Fig. 1). Early gene
activity, as revealed by the presence of surrogate markers,
never persisted to the epithelial surface in areas of productive
viral infection but showed a pattern that was characteristic of
each infecting papillomavirus type (Fig. 1). Oral lesions caused
by COPV typically expressed PCNA in basal cells and in spo-
radic cells immediately above them—a pattern of expression
similar to that seen in human cutaneous lesions (verrucas)
caused by HPV1 (data not shown and reference 42) and HPV2
(Fig. 1A). Oral and penile lesions caused by ROPV (17) usu-
ally showed more extensive early gene activity, with PCNA
being detected throughout the epithelium (an oral papilloma is
shown in Fig. 1B). This pattern is similar to that seen in human
mucosal lesions caused by HPV11 and HPV16 (an LSIL is
shown in Fig. 1B). Lesions caused by HPV16 do not always
support the productive stages of the virus life cycle, however,
and under these circumstances, markers of early gene expres-
sion can be found in cells at the epithelial surface (data not
shown and K. Middleton, L. Morris, W. Peh, A. El-Sherif, K.
Sotlar, D. Jenkins, R. Seth, H. Grifﬁn, H. Hibma, R. Laskey, N.
Coleman, and J. Doorbar, 19th Int. Papillomavirus Conf., ab-
str. P-21, 2001). This is a characteristic of high-grade squamous
intraepithelial lesions (HSIL) caused by HPV16 and was not
seen during productive infection.
CRPV and BPV infect cutaneous epithelium, making com-
parison with human mucosal infections more difﬁcult. BPV-
induced papillomas from cattle and CRPV-induced papillomas
from cottontail (natural host) and New Zealand White (arti-
ﬁcial host) rabbits express markers of viral oncogene expres-
sion above the basal layer (a cottontail rabbit papilloma is
shown in Fig. 1A). The distributions of PCNA were broadly
similar in papillomas induced in both rabbit hosts, even though
New Zealand White rabbits do not support the full CRPV life
cycle. In Fig. 1, DNA in situ hybridization was used to identify
cells supporting late events during the life cycle of CRPV, as
the CRPV E4 antibodies gave relatively high levels of back-
ground staining (Fig. 2B). The distribution of surrogate mark-
ers of early gene expression in CRPV-induced papillomas in
their natural host resembled that seen in LSIL caused by
HPV11 and -16 and in oral papillomas caused by ROPV (Fig.
1). The expression of such markers without the subsequent
onset of late events was seen only in lesions produced in New
Zealand White rabbits (artiﬁcial host) and HSIL caused by
HPV16 (data not shown).
Heterogeneity in the timing of late-stage onset in lesions
caused by animal and human papillomaviruses. The late stage
of the virus life cycle is triggered only as the infected cell
migrates towards the epithelial surface. Although E6 and E7
are difﬁcult to detect by immunostaining, E4 is abundantly
expressed and can be detected during epithelial cell differen-
tiation by using type-speciﬁc antibodies. The expression of E4
has previously been shown to coincide precisely with the onset
of vegetative viral genome ampliﬁcation in lesions caused by
HPV1 and HPV16 (42), and in the ﬁrst instance we sought to
establish that this was a common event in the life cycles of all
papillomavirus types. To establish this, antibodies were gener-
ated to the E1E ˆ4 major late proteins of ROPV, CRPV, COPV,
and BPV after expression as fusion proteins in bacteria. Anti-
bodies to the E1E ˆ4 proteins of HPV2, HPV11, HPV63, and
HPV65 were also generated for comparison. In all cases, high-
afﬁnity antibodies were obtained which allowed detection of
the appropriate E4 protein in biopsy material. With the excep-
tion of antibodies to the BPV1 and HPV11 E4 proteins, which
cross-reacted with the E4 proteins of BPV2 and HPV6, respec-
tively, the antibodies did not cross-react between virus types.
Antibodies to the E1E ˆ4 proteins of HPV1 and HPV16 have
been described previously (39, 41, 42). No staining was appar-
ent using preimmune serum.
In all the human and animal papillomaviruses examined,
genome ampliﬁcation coincided with the presence of detect-
able levels of E4, although as with early events, the life cycles
of the different viruses showed variation. The most unexpected
observation was that viral genome ampliﬁcation and the ex-
pression of E4 begins in cells of the basal layer in oral lesions
caused by COPV (Fig. 2A). Most basal cells express PCNA
(Fig. 1A), but in lesions caused by COPV, a subset of these
express E4 (Fig. 1A) and support viral genome ampliﬁcation
(Fig. 2A) (73). Viral genome ampliﬁcation in the basal layer
was not observed in lesions caused by other papillomavirus
types, although HPV1 and -63 (to which COPV is closely
related [24, 34]) and HPV65 do initiate genome ampliﬁcation
in cells of the lowest parabasal layers (Fig. 2A) (42). These
viruses cause verrucas rather than oral papillomas. By contrast,
ROPV, HPV11, and HPV16 (LSIL) showed similarity in the
timing of their late events (Fig. 2B). In both cases, genome
ampliﬁcation and E4 expression coincided in the mid-spinous
layers, with E4 being detectable to the epithelial surface (Fig.
2B). A correlation between the detection of E4 and the onset
of genome ampliﬁcation was also observed in lesions caused by
BPV1 (data not shown) and CRPV (Fig. 2B). The timing of
late events in CRPV-induced lesions generated in cottontail
rabbits resembled that seen in productive human lesions
caused by HPV11 and HPV16 (LSIL) and was distinct from
the “sporadic” pattern seen in human cutaneous papillomas
caused by related viruses, such as HPV63 (24) (Fig. 2).
Although the association between the appearance of detect-
able levels of E4 and the onset of viral genome ampliﬁcation
was a common feature of all the lesions examined here, high
levels of viral DNA were occasionally seen in the absence of E4
in lesions caused by COPV, as well as in lesions caused by
CRPV (Fig. 2B and 3). In CRPV-induced lesions (Fig. 2B),
such cells appear to arise from E4-expressing cells (present in
the spinous layer) that are supporting viral genome ampliﬁca-
tion, and we assume that E4 does not persist to the epithelial
surface or that the antibody is not able to detect it in the upper
epithelial layers. Although this may also be true of the cells
that contain ampliﬁed viral genomes (but not E4) in lesions
caused by COPV, the sporadic distribution of E4-containing
cells in these lesions makes this less evident. We do not know
for certain whether the in situ signals seen in the E4-negative
cells in COPV-induced lesions represent true genome ampli-
ﬁcation or a partial relaxation of the copy number control that
operates in the basal layer. Cells containing ampliﬁed viral
10406 PEH ET AL. J. VIROL.genomes in the absence of E4 were not seen in lesions caused
by other papillomavirus types.
The onset of late events is closely linked to the completion of
early events during the papillomavirus life cycle. Although our
data show that the timing of the late-event activation is diver-
gent among papillomavirus types, a high degree of consistency
was apparent when lesions caused by the same virus type were
compared. This was most evident in papillomas induced by the
evolutionarily related viruses (24) COPV, HPV1, and HPV63,
which trigger late gene expression in the basal and parabasal
cell layers (Fig. 1 and 4). Over 60% of the cells in the upper
epithelial layers of such lesions express E4, with such cells
usually appearing in clusters—a distribution that is also seen in
lesions caused by BPV1 (Fig. 4). No variation in this pattern
was apparent in 8 COPV-induced oral papillomas and 25
HPV1-HPV63-induced verruca lesions examined. Lesions
caused by CRPV in its natural host, ROPV, HPV11, and
HPV16 (LSIL) also showed consistency in their patterns of late
gene expression (which began in the intermediate layers), but
these were distinct from the patterns seen in oral lesions
caused by COPV and in cutaneous lesions caused by HPV1,
HPV2, or HPV63 (Fig. 4). The expression pattern character-
istic of each papillomavirus type is shown in Fig. 4. Despite the
heterogeneity among viruses, the disappearance of early mark-
ers always occurred after the onset of late events, suggesting
that the two stages in the virus life cycle are closely coordinated
(Fig. 1). Cells expressing both E4 and viral oncogenes, such as
E7 (as determined by the presence of surrogate markers), were
found in a narrow region of overlap, which could be as little as
one cell layer thick in LSIL caused by HPV16 (Fig. 1B) to over
ﬁve cell layers thick in COPV-induced oral papillomas or cu-
taneous warts caused by HPV2 (Fig. 1A). The overlap between
surrogate markers of viral early gene activity (e.g., PCNA and
cyclin A) and late markers (e.g., E4 and genome ampliﬁcation)
shown in Fig. 1 was a common feature of all the productive
papillomavirus infections examined here. Only during abortive
infection, such as in HPV16-associated HSIL or in lesions
produced by CRPV in New Zealand White rabbits (artiﬁcial
host), is this pattern of expression disrupted.
Intracellular distribution of E4 in lesions caused by animal
papillomaviruses. The E4 proteins of many papillomaviruses
form intracellular structures that are characteristic of the in-
fecting virus type. While this is particularly evident in lesions
caused by HPV1 and HPV4 (38), it has been suggested that
most cutaneous viruses form some sort of cytoplasmic inclu-
sion (32, 46, 47, 70). By contrast, the E4 proteins of human
mucosal viruses do not produce inclusions (19, 21, 40, 42, 81).
HPV16 E4 associates with the cellular intermediate ﬁlament
network, whereas HPV11 E4 localizes to the corniﬁed enve-
lope of the cell. E4 is one of the few viral proteins that can
easily be detected during productive infection, and the gener-
ation of antibodies allows its intracellular distribution to be
examined. Although the role of E4 is uncertain, similarities in
intracellular localization may suggest functional conservation.
Of the viruses examined here, only ROPV E4 had an in vivo
intracellular distribution that broadly resembled that of the
human mucosal viruses. The E4 proteins of HPV16 and
HPV11 are predominantly cytoplasmic, and this was also true
of ROPV E4 (Fig. 5A). Unlike the E4 proteins of HPV16 and
HPV11, however, ROPV E4 assembled into cytoplasmic inclu-
sion granules similar to those seen in warts caused by HPV1
(82, 83), and these increased in size as the cells approached the
epithelial surface (Fig. 5A). Granule formation is an inherent
property of the E4 proteins of HPV1 and ROPV and also
FIG. 3. E4 expression and the onset of genome ampliﬁcation are not necessarily coincident. (A and B) Tissue sections taken from two different
COPV-infected oral lesions. Tissue sections were double stained for the presence of viral genome ampliﬁcation (DNA) and for E4 expression (E4).
Viral DNA was occasionally detected in the absence of E4 (cells indicated by arrows). The nuclei were counterstained using Sytox green (nuclei).
(B) E4 expression in cells (indicated by arrowheads) that are not supporting viral genome ampliﬁcation. A cell (indicated by an arrow) supporting
viral genome ampliﬁcation but lacking E4 is shown in the same ﬁeld of view. The images were taken using a 40 objective.
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82, and 83 and our unpublished results).
Although E4 is predominantly cytoplasmic in all the human
papillomavirus infections examined to date (17, 38, 42), in
lesions caused by COPV and CRPV the protein was distrib-
uted throughout the cell (Fig. 5). Cells expressing COPV E4
contained cytoplasmic structures that were similar in appear-
ance to the inclusions produced by ROPV (Fig. 5A and C).
COPV E4 protein was also associated with the nucleoli (Fig.
5D) and with cell membranes (Fig. 5C). Although CRPV E4
was not associated with any obvious structures, lesions caused
by CRPV and COPV contained abundant keratohyalin gran-
ules. In CRPV-induced warts, these were found in the cells
expressing E4 (Fig. 5B). Mucosal epithelium, such as that
infected by COPV and ROPV, does not normally contain
abundant keratohyalin granules (Fig. 5C, inset), making their
presence in COPV-infected tissue surprising. Keratohyalin
granules were not, however, present in cells expressing COPV
E4. This is similar to the situation seen in lesions caused by
HPV1, where E4-expressing cells lack ﬁlaggrin and do not
produce visible keratohyalin (42). Although ROPV and COPV
infect similar epithelial sites, keratohyalin granules were never
detected in lesions caused by ROPV and were only occasion-
ally present in human mucosal infections caused by HPV11
and -16 (data not shown).
Expression of E4 always precedes expression of the L1 cap-
sid protein. The major virus coat protein was expressed in the
nuclei of terminally differentiating cells near the surface of the
epidermis. In all the lesions examined here, L1 expression
followed that of E4, and a gap was apparent between the ﬁrst
appearance of E4 and the ﬁrst appearance of L1 (Fig. 6).
Although L1 expression was ﬁrst detected in E4-containing
cells, L1 expression was not always supported, and cells ex-
pressing only E4 could occasionally be found at the epithelial
surface. This was sometimes apparent in productive infections
(e.g., HPV11 [Fig. 6]) but was seen more regularly in HSIL
caused by HPV16. Such lesions resemble those produced in
New Zealand White rabbits by CRPV and do not support the
full life cycle of the virus (data not shown and Middleton et al.,
19th Int. Papillomavirus Conf.). While the coordinated pattern
FIG. 4. Timing of late events is highly conserved among lesions caused by the same papillomavirus type. Similarities in the patterns of E4
expression and genome ampliﬁcation conﬁrmed that E4 was an effective marker of the late stages of the papillomavirus life cycle. Tissue biopsies
infected by different papillomaviruses were sectioned and stained using E4-speciﬁc antibodies (green) before being counterstained with DAPI
(blue). The staining patterns illustrated were typical of those seen following the examination of ﬁve or more independent biopsy specimens infected
by each virus type (except for HPV63, for which three lesions were examined [see Materials and Methods]). The timing of late-stage onset was
a characteristic feature of each infecting virus type. All images were taken using a 4 objective except for the HPV16 and CRPV images, which
were taken using a 10 objective lens. The basal layers are indicated by the broken lines.
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examined, the gap between the ﬁrst appearance of E4 and the
onset of L1 expression varied considerably. Viruses that initi-
ate their late events in the lower epithelial layers, such as
COPV, HPV1, and HPV63 (which are evolutionarily related
[24]), typically showed a greater number of L1-expressing cells
than those that initiate late gene expression in the upper epi-
thelial layers (compare COPV and HPV11 in Fig. 6). LSIL
caused by HPV16 and cutaneous papillomas caused by CRPV
(in the cottontail rabbit host [Fig. 6]) had intervals as small as
one or two cell layers between the site of E4 expression and
that of L1. Cutaneous lesions caused by HPV1 and HPV2 (Fig.
6) usually initiated L1 expression four or ﬁve cell layers after
the ﬁrst appearance of E4. By contrast, L1 expression in
HPV63- or COPV-induced lesions may be separated from the
onset of E4 expression by as many as 20 cell layers (42) (Fig. 6).
Of the lesions examined here, those caused by HPV11 and
ROPV showed the greatest similarity in the expression pat-
terns of their E4 and L1 proteins, although E4 expression in
ROPV lesions usually began earlier than in lesions caused by
HPV11 (Fig. 6).
Viral gene expression in xenografts resembles that seen
during infection of the natural host. Several papillomaviruses,
including ROPV (28), CRPV (30), and HPV11 (36, 63), can be
propagated in epithelial tissue implanted under the renal cap-
sule. This approach has been used to generate stocks of animal
(28) and human papillomaviruses and to study the HPV life
cycle in vivo (18, 20). Renal-capsule xenografts infected with
CRPV or ROPV were compared to experimental infections in
their natural hosts with regard to the timing of initiation of late
events described above. The lesions produced in both systems
were broadly similar, and the timing of E4 expression, genome
ampliﬁcation, and virus synthesis (described here) was pre-
served (Fig. 7). Detectable E4 expression began in the inter-
mediate and spinous cell layers and coincided with the onset of
viral genome ampliﬁcation (ROPV is shown in Fig. 7). Al-
though genome ampliﬁcation was not examined in CRPV-
infected xenografts, the expression of CRPV E4 followed a
pattern that resembled that seen during natural infection (Fig.
4 and 7). In all xenografts examined, irrespective of the infect-
ing papillomavirus type, the L1 protein was ﬁrst expressed in
only a subset of E4-positive cells in the upper layers of the
epidermis (HPV11 is shown in Fig. 7). Xenografts propagated
under the kidney capsule, however, did show a lower degree of
papillomatosis than lesions produced at the natural site of
infection, as reported previously (8). It appears that L1 expres-
sion always follows that of E4, in contrast to previous reports,
which have indicated that the expression of E4 and L1 is
coincident (18, 20). HPV11 xenografts propagated on the skin
(in SCID mice) showed similarity to naturally occurring human
genital lesions both in their morphology and in their pattern of
late gene expression (compare Fig. 1, 2, 4, and 6 and
HPV11SCID/E4 and -L1 in Fig. 7).
DISCUSSION
Papillomaviruses are highly host speciﬁc, making the use of
animal models a valuable strategy for the in vivo analysis of
infection. CRPV has been extensively used for the develop-
ment of vaccines (16, 53, 54, 65, 87, 94) and has provided
insight into the roles of viral proteins during papilloma forma-
tion (13, 14, 33, 72, 104). Vaccination studies have also been
carried out using COPV, which, unlike CRPV, infects oral
epithelium (5, 91, 95, 105). Although the mucosal tropism of
COPV has led to its use as a model of genital HPV infections,
the COPV life cycle differs in several ways from those of
HPV11 and HPV16. At the DNA and protein sequence levels,
COPV shows homology with HPV types that cause plantar and
palmar warts, and this is reﬂected in similarities among lesions
caused by these viruses (24). Of the papillomaviruses examined
here, the COPV E4 protein resembles the E4 proteins of
HPV4 and HPV65 most closely, while its E6 protein shows the
greatest sequence homology with the E6 proteins of HPV1 and
-63. The initiation of late events in basal and parabasal cell
layers is a characteristic of these related virus types and is an
obvious difference between lesions caused by COPV and those
caused by CRPV, ROPV, HPV11, and HPV16 (summarized in
Fig. 8). Interestingly, COPV-infected cells contained inclusions
that were similar in appearance to those seen in lesions caused
by HPV1 and ROPV. The E4 proteins of COPV and ROPV
contain variants of the C-terminal DLXDYW motif that is
found in cutaneous human papillomaviruses and which is in-
volved in E4 multimerization (2). This motif has not previously
been identiﬁed in the E4 proteins of mucosal papillomavirus
types (44). If vaccination studies using model systems are to be
relevant in the prevention and treatment of human disease, the
chosen model should closely mimic infection in humans.
COPV and HPV11 have similar tissue tropisms but differ in the
timing of their life cycle events (Fig. 8). By contrast, the life
cycles of HPV11, HPV16, and ROPV (which all infect genital
tissue) are organized similarly. The ability of New Zealand
White rabbits to support the full ROPV life cycle makes this
system useful for the study of late gene function, but the short
duration of the experimental ROPV-induced papillomas may
limit its use to the development of prophylactic vaccines. Al-
though experimental papillomas caused by CRPV do not sup-
port late events, they are persistent and offer some advantages
in the development of therapeutic vaccines and antivirals.
It has been suggested that papillomaviruses evade immune
detection, at least in part, by expressing their abundant late
proteins only in the upper epithelial layers (86, 89, 92). Viral
early proteins, such as E6 and E7, are expressed at levels below
those necessary to stimulate an effective immune response.
While this hypothesis is plausible for human mucosal infec-
tions, it does not explain the results obtained here from the
analysis of lesions caused by HPV1, HPV65, or COPV, where
high levels of E4 are apparent in the basal and parabasal layers
(Fig. 4 and 8). Unlike those caused by HPV16 or HPV11,
naturally occurring lesions induced by COPV are rarely per-
sistent (74) and usually undergo spontaneous regression within
12 weeks of infection (23). Perhaps signiﬁcantly, plantar warts
caused by HPV1 (myrmecia) are also often short-lived (52).
Such lesions usually respond to treatment better than plantar
warts caused by HPV2 (mosaic warts) and rarely recur, due to
the presence of neutralizing antibodies (64, 80). Little is known
of the natural history of verrucas caused by HPV63 and
HPV65, but it is possible that wart persistence may be linked to
an ability to retard the expression of E4 and capsid proteins
until the cell has cleared the basal layer. If this is the case, then
infections caused by HPV11 and HPV16 may be more persis-
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rapid regression of genital lesions caused by HPV6 or -11 is
relatively uncommon and usually occurs following a period of
wart proliferation, as can often occur during pregnancy (7, 76,
96). HPV16 infections vary greatly in duration (57, 99) and also
show variation in the timing of their late gene expression.
Persistent infections caused by HPV16 (at cervical epithelial
sites) and CRPV (in New Zealand White rabbits) are associ-
ated with an increased risk of malignant progression (31, 62,
101). Although there is as yet no ﬁrm evidence to link the
duration of infection with the extent of virus synthesis, many
reports have revealed the importance of the host immune
system in restricting papilloma growth and in stimulating re-
gression (reviewed in references 56 and 89). The exposure of
viral late proteins to the immune system can prevent papillo-
mavirus spread and can stimulate the early regression of exist-
ing warts (reviewed in references 15 and 59).
The rapid regression of experimental warts caused by COPV
and ROPV may be related to the fact that they were induced
by scariﬁcation using concentrated virions. Under these con-
ditions, an immune response to infecting virions is generated
(29, 75), and it is not unreasonable to think that this may also
occur during natural infection if the titer of the infecting virus
is high. Papillomaviruses may thus have reached a balance
between the need to produce high numbers of virus particles
and the need to evade detection by the host’s immune system.
The initiation of late events in the basal and parabasal layers is
compatible with the high-level production of virions, as occurs
in warts caused by HPV1 (4). For viruses such as these (e.g.,
HPV65 [verrucas] and COPV [canine oral papillomas]), where
transmission by intimate physical contact is unlikely, the
chance of initiating a new infection is enhanced. Papillomavi-
ruses that are transmitted by intimate physical contact, such as
those that infect genital sites (e.g., HPV16), may be required at
lower levels. The low abundance of HPV16 virions in many
genital lesions may be an evolutionary adaptation that ensures
that an immune response to infection does not occur.
Differences in the target tissue and the type of contact nec-
essary for transmission may provide some explanation for the
life cycle heterogeneity seen in this study. The four animal and
six human papillomaviruses examined have diverse natural his-
tories, and it is perhaps not surprising that they show differ-
ences in their patterns of gene expression following infection
(Fig. 8). All papillomaviruses, however, must replicate and
package their DNA, and certain features were found to be
conserved among the life cycles of all the viruses examined. A
correlation between E4 expression and viral genome ampliﬁ-
cation has previously been observed from the analysis of le-
sions caused by HPV1 and HPV16 (42) and from the analysis
of cell lines containing HPV DNA (84). The discovery that E4
expression correlates closely with genome ampliﬁcation in nat-
ural and experimental infections caused by a diverse collection
of papillomaviruses supports the assumption that this is a con-
served event. In most of the papillomaviruses that have been
examined to date, E4 is expressed from a differentiation-de-
pendent promoter late in infection (37). In human papilloma-
viruses, this promoter is positioned in front of the E1 helicase,
which is known to have a direct role in the replication of viral
genomes (reviewed in references 25 and 35). The E1E ˆ4 mR-
NAs share the same initiation codon, and the relative abun-
dances of the two messages are controlled at the level of splice
site selection. This apparent link between the synthesis of full-
length E1 transcripts and the production of the primary E1E ˆ4
message suggests that the two proteins may be required to-
gether during the virus life cycle. In fact, E4 appears to be
expressed as part of a single transcriptional unit that also
includes E1, E2, and E5. E5 reactivates DNA synthesis in
quiescent cells (1, 10, 93, 98, 100), while E2 is necessary for the
efﬁcient recruitment of E1 to viral origins (49, 67). Interest-
ingly, a role for HPV16 E4 in genome ampliﬁcation has re-
cently been proposed (C. Davy, D. Jackson, K. Raj, P. Master-
son, J. Millar, and J. Doorbar, 19th Int. Papillomavirus Conf.,
abstr. O-174, 2001), and it has been shown that loss of E4
prevents ampliﬁcation of the CRPV genome in domestic and
cottontail rabbits (W. Peh, J. Brandsma, N. Cladel, N. Chris-
tensen, and J. Doorbar, 19th Int. Papillomavirus Conf., abstr.
O-146, 2001).
E4 expression and the onset of genome ampliﬁcation were
always found to begin in cells expressing surrogate markers of
early gene activity, such as PCNA or cyclin A (Fig. 1 and 8).
The viral E6, E7, and E5 proteins drive cells into S phase and
stimulate the synthesis of the cellular proteins necessary for
viral genome ampliﬁcation. The region where E4-PCNA dou-
ble-positive cells were found varied greatly in thickness in
FIG. 5. Intracellular distribution of the E4 proteins of animal papillomaviruses. (A) The E4 protein of ROPV (red) is predominantly
cytoplasmic and is associated with inclusion granules (center image, g) similar to those seen in cutaneous lesions caused by HPV1. The nuclei were
counterstained with DAPI (blue) and are visible in the merged image at the left (ROPV/m). The E4 granules (g) are also shown in the hematoxylin-
and eosin-stained image at the right (labeled ROPV/HE). The images were taken using a 40 objective. (B) The E4 protein of CRPV (green)
is distributed throughout the nucleus and the cytoplasm. The nuclei were counterstained with DAPI (blue) and are visible in the merged image
shown on the left (CRPV/m). The cytoplasmic structures that did not stain with antibodies to E4 are keratohyalin granules (center image, arrows).
They are also shown (KH) in the hematoxylin- and eosin-stained image (CRPV/HE) on the right. (C) The E4 protein of COPV (green) was
cytoplasmic and nuclear but was also associated with the nuclear and cellular periphery (upper center image, arrow). The nuclei were counter-
stained with either propidium iodide (upper left image, red) or DAPI (lower left image, blue). A granular pattern was apparent in the cytoplasm
of some cells (granule-like structures [arrows] in lower center image). Keratohyalin granules (KH) are abundant in COPV-induced warts and are
shown in the hematoxylin- and eosin-stained image (COPV/HE; upper right). The surrounding mucosal epithelium is devoid of keratohyalin
(inset). Cells expressing COPV E4 had a characteristic morphology that may result from the presence of E4 inclusion granules. The permissive
cells (P) that express E4 and the nonpermissive cells (NP) that do not express E4 are shown in the hematoxylin- and eosin-stained image on the
lower right. (D) In the lower epithelial layers of experimental warts caused by COPV, nuclear E4 protein (green) was found associated with the
nucleoli. At the left (COPV/m), the E4 and DAPI (blue) stain is shown as an overlay of the phase-contrast image. The phase-contrast image is
shown in the center panel to indicate the presence of the nucleoli (NUC). The presence of the permissive “granular” cells (P) and the nucleoli
is clearly visualized in the immunoperoxidase stain (brown) shown on the right [COPV/E4 (DAB)].
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caused by COPV, ROPV, HPV11, CRPV, and HPV2 were double stained using antibodies to the L1 capsid protein (red) and E4 (green) before
being counterstained with DAPI (blue). The merged images (m) are shown on the left. Although E4 expression always precedes the expression
of L1, the distance between the ﬁrst appearance of E4 and the ﬁrst appearance of L1 varied considerably. The positions of the basal layers are
indicated by broken lines. The images were taken using a 10 (HPV2, HPV11, and COPV) or 20 (CRPV) objective.
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positive cells were abundant, while in lesions caused by HPV16
they were scarce. The increase in the levels of the viral repli-
cation proteins E1 and E2 that result from the activation of the
differentiation-dependent promoter are thought to contribute
to genome ampliﬁcation (6, 61, 78, 79). Our observation that
markers of E6 and E7 expression are lost soon after the ap-
pearance of E4 can be readily explained if the levels of E2 and
E4 rise concomitantly. Both E2 and E4 are expressed from the
differentiation-dependent promoter late in infection (26, 27,
42), with E2 showing an expression pattern similar to that of
E4 (66). High-level expression of E2 leads to down-regulation
of the viral early promoter and inhibition of E6 and E7 ex-
pression. Although E2 is necessary for the ampliﬁcation of
viral genomes, its accumulation may eventually restrict the
duration of vegetative viral DNA replication by down-regulat-
ing the expression of E7.
Our comparison of the life cycles of 10 viruses reveals differ-
FIG. 7. The timing of late gene expression in xenografts resembles that seen during natural infection. Epithelial tissue infected by CRPV or ROPV
was propagated under the kidney capsule of nude mice (images labeled CRPVNUDE and ROPVNUDE) before being stained for E4 and (for ROPV)
genome ampliﬁcation. The nuclei were counterstained with DAPI and are shown on the left. In all cases, the timing of late-stage activation (as determined
by E4 expression) was similar to that seen following natural and experimental infection of the natural host (Fig. 4). Genome ampliﬁcation and E4
expression coincided closely (images labeled ROPVNUDE/DNA and ROPVNUDE/E4). Epithelial tissue infected by HPV11 was propagated under the
kidney capsule of nude mice or as a skin graft in SCID mice. L1 expression followed that of E4 in renal capsule xenografts infected with HPV11 (images
labeled HPV11NUDE/E4 and HPV11NUDE/L1). This pattern of expression was also seen in skin grafts propagated on SCID mice (HPV11SCID/E4
and HPV11SCID/L1). The morphology of the skin xenografts closely resembled that seen in HPV11-induced genital lesions (Fig. 2 and 4). The images
were taken using a 10 (ROPV and HPV11) or 20 objective. The broken lines indicate the positions of the epithelial basal layers.
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virus transmission routes and infection sites. Key life cycle events,
such as the onset of genome ampliﬁcation and virus assembly, are
likely to be similarly regulated in all papillomaviruses, and current
theories of protein function effectively explain the expression pat-
terns seen here. The major differences between different viruses
appear to lie in the timing of events. As far as we are aware, this
is the ﬁrst comparative study of animal and human papillomavirus
life cycles despite the extensive use of animal papillomaviruses to
study infection in humans. BPV1 has been used most extensively
to study the role of the viral transforming proteins because of its
ability to replicate in ﬁbroblasts in vitro and to transform them.
Although studies of the BPV life cycle have been carried out (1,
68), it is not a convenient animal model system, and it is generally
acknowledged that the results obtained from the study of BPV
may not be directly applicable to our understanding of HPVs.
CRPV, which, unlike BPV, is not a ﬁbropapillomavirus, has been
used more extensively as a model system for human infections.
The timing of life cycle events in lesions caused by CRPV closely
resembles that seen in human lesions caused by HPV11 and
HPV16, and studies of the immune response to viral early pro-
teins in CRPV are likely to be relevant to infection by human
viruses (87). This should also be true for studies that use CRPV
to investigate the mechanism of malignant progression (62, 106)
and the roles of viral early proteins during cell proliferation and
genome ampliﬁcation (14, 104; Peh et al., 19th Int. Papillomavirus
Conf.). The inability of CRPV to infect mucosal tissue and to go
through its productive life cycle in laboratory animals limits its
value as a model of productive genital infections. Of the mucosal
models of human papillomavirus infection that are currently
available, it appears that ROPV offers advantages over COPV.
ROPV infects rabbits rather than dogs and, unlike COPV, can
cause lesions at genital sites (90). The timing of events during the
life cycle of ROPV is more similar to those of HPV11 and
HPV16, and genome ampliﬁcation in the basal layer does not
occur. This may be important for vaccination studies. Vaccination
of dogs using virus late proteins (95, 105) stimulates antibody
production and partially protects the vaccinated animals from
high-dose viral infection. A similar approach is being used to
develop a prophylactic vaccine for the treatment of human genital
lesions (85). Therapeutic-vaccination strategies however, aim to
resolve existing infections and rely on the ability to generate a
cell-mediated immune response to virus-infected cells. The site of
infection (mucosal versus cutaneous) and the timing of events
during the virus life cycle are likely to affect the outcome of such
experiments. Similarities in the site of infection and the timing of
life cycle events suggest that ROPV may be particularly appro-
priate for life cycle and prophylactic-vaccine studies. The longer
duration of nonproductive infections, such as those caused by
CRPV in domestic rabbits, offers advantages for the development
of therapeutic vaccines and antiviral therapies.
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